Moving beyond the conventional sequential Phase I→II→III drug development pathway, robust population PK/PD models are constructed using pooled Phase I clinical pharmacology datasets. Model-derived exposure-response relationships together with efficacy and safety biomarkers provide solid regulatory evidence to support a Phase II trial waiver, enabling direct progression to Phase III pivotal trials and substantially shortening clinical development timelines while lowering overall R&D costs.